Oral anticoagulants decrease ischemic stroke rates in patients with atrial fibrillation (AF) but increase the risk of bleeding. For the average patient with AF, the threshold of annual ischemic stroke rate where the benefit of anticoagulation outweighs the bleeding risk (net clinical benefit) has been shown to be ≈1% to 2%. Guideline recommendations for oral anticoagulants in AF are based on the CHA 2 DS 2 -VASc stroke risk point scores, assuming that those scores translate to fixed stroke rates. However, the relationship between stroke point scores and annual stroke rates may vary substantially across populations. We sought to comprehensively assess the reported rates of stroke in patients with AF and the relationship of stroke rates to stroke risk point scores.
O ral anticoagulants (OACs) dramatically reduce the risk of ischemic stroke in patients with nonvalvular atrial fibrillation (AF). 1 However, OAC therapy also increases the risk of bleeding complications, including intracranial hemorrhage, which is often fatal. The anticoagulation decision should be based on the expected net clinical benefit of OAC (ie, the difference between the reduction in stroke risk and increase in bleeding risk after weighing the severity of stroke and bleeding outcomes). 2 The risk of ischemic stroke varies among patients with AF, and those at low risk may have little, no, or negative net clinical benefit from anticoagulation. The expected net clinical benefit for OAC treatment tends to track with the absolute stroke risk, and decision analyses have indicated that the threshold at which OAC treatment yields a net clinical benefit is a stroke risk of 1% to 2% per year. 3 The CHA 2 DS 2 -VASc stroke risk scoring system, which assigns 1 point each for a history of congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65 to 74 years, and sex category (female sex), and 2 points for age ≥75 years, and prior stroke/ transient ischemic attack, has now become the standard for most leading guidelines including the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) and European Society of Cardiology (ESC). 4, 5 The CHA 2 DS 2 -VASc score uses patient characteristics (Table 1) to create a point score, with increasing point scores corresponding to higher risks of ischemic stroke. The ESC guidelines recommend using OAC at a CHA 2 DS 2 -VASc score of 1 or 2 greater, depending on patient sex, and the AHA/ACC/ HRS guidelines recommend OAC at a CHA 2 DS 2 -VASc score of 2 or greater.
However, these guideline recommendations assume that CHA 2 DS 2 -VASc point scores correspond to fixed stroke rates. The guidelines cite stroke rates from a few primary source cohorts, [6] [7] [8] but rates from other cohorts may differ significantly. Our study sought to review the reported rates of stroke in patients with AF not taking OACs in all cohorts reported worldwide and assess the consistency of these rates with those cited in the AHA/ ACC/HRS and ESC guidelines.
METHODS Study Selection
In consultation with librarian services at Countway Library of Medicine in Boston, MA, we used PubMed to perform a systematic review of the literature ending November 23, 2015 , to identify all cohort and randomized controlled trials that included patients with AF who were not taking OACs and reported either person-year rates of ischemic stroke, thromboembolism, or transient ischemic attack or the data needed to calculate those rates. Whenever sufficient data were available, only ischemic strokes were used in rate calculations and both systemic thromboembolism and transient ischemic attack were excluded. We chose to include only patients or person-years off OACs because nonanticoagulated stroke risk drives the anticoagulation decision 9, 10 and imputing such risk from rates observed on anticoagulants is based on the uncertain assumption that the effect of OAC is constant across risk strata. Studies that included both patients on and off OACs were eligible if they reported separate data for patients not on
Clinical Perspective
What Is New?
• Guidelines for anticoagulation in atrial fibrillation suggest using the CHA 2 DS 2 -VASc scoring system for determining the anticoagulation threshold, assuming that CHA 2 DS 2 -VASc scores correspond to fixed stroke rates. • Our study demonstrates wide variation in overall and CHA 2 DS 2 -VASc point score-stratified stroke rates across atrial fibrillation cohorts.
• The American Heart Association/American College of Cardiology/Heart Rhythm Society and European Society of Cardiology guidelines do not highlight this variation in stroke rates and cite stroke rates predominantly from sources that have significantly higher rates than those observed in other cohorts.
What Are the Clinical Implications?
• The inconsistency between CHA 2 DS 2 -VASc stroke risk point scores and absolute stroke rates can substantially change the expected net clinical benefit of anticoagulation in any given patient with atrial fibrillation.
• These results call into question the generalizability of current leading guideline recommendations that CHA 2 DS 2 -VASc scores of 1 and 2 points should serve as the threshold for use of anticoagulant therapy.
• The majority of worldwide cohorts did not observe stroke rates high enough to indicate a clear expected net clinical benefit for anticoagulating atrial fibrillation patients with CHA 2 DS 2 -VASc scores of 1 or 2. OACs. Patients on antiplatelet agents were allowed and, when possible, were included in the rates. If enough data were not available to combine results from patients taking antiplatelet agents with those taking no antithrombotic therapy, then data from the group taking no antithrombotic therapy were used. If rates from multiple follow-up time periods were reported, then we used rates from 1-year follow-up to allow more consistent comparisons between cohorts. When multiple reports existed in the literature that used the same patient database, first preference was given to the most complete analysis in which all study criteria were met, second preference to the original paper describing the database, and third preference to the paper that contained the most detailed data describing the stroke rates. The same database could contribute to the analysis multiple times if reports from the cohorts differed significantly from each other (eg, they used the same database but analyzed the data during a different time period). Databases included in more than 1 identified paper (eg, pooled analyses) were only included once to ensure they would not be counted in the analyses multiple times. We excluded studies that only enrolled patients who were undergoing procedures such as catheter ablation or cardioversion; patients with specific conditions such as hypertrophic cardiomyopathy, end stage renal disease, or myocardial infarction; patients with pacemakers; or patients who had experienced previous strokes because they did not represent a general AF population. Studies that did not present data for ischemic stroke separate from hemorrhagic stroke or explain their methodology for identifying ischemic strokes from other types of strokes were also excluded because the outcome of interest was ischemic stroke alone.
Results of the literature review were compiled into 2 groups of studies: (1) an overall stroke rate group for which the annualized stroke rate of the entire population not taking OACs was reported or could be calculated, and (2) a CHA 2 DS 2 -VASc point score stratified group, which included studies that reported stroke rates for specific CHA 2 DS 2 -VASc point scores. Any particular study could be part of either or both groups. Studies that restricted their population to only certain stroke risk scores (eg, only low-risk patients) were not included in the overall stroke rate group but could be used in the CHA 2 DS 2 -VASc score-stratified analyses.
Statistical Analysis
The quality of each individual cohort study was assessed using the Newcastle-Ottawa Scale 11 by 2 independent raters (G.Q. and O.S.), and disagreements were discussed and adjudicated by a third rater (D.S.) when necessary. Based on the Poisson distribution, event rates per 100 person years, variance, and confidence intervals were calculated for each individual study by summing person-years and number of events directly taken from reports. Heterogeneity between studies was summarized by the I 2 and Q statistics and investigated using the χ-square test. 12 Cohort studies were categorized by region of the population (North America, Europe, Asia, and Middle East) and study design (randomized controlled trials, prospective cohorts, or retrospective cohorts). The midpoint year of the follow-up period (rounded up to the nearest year) and outcome event cluster (ischemic stroke only, ischemic stroke and transient ischemic attack, or all thromboembolisms) was also recorded for each study. Because of the heterogeneity of event rates across studies, we conducted a mixed-effect Poisson regression to examining the effects of region, prospective versus retrospective design, midpoint year of follow-up, and outcome event cluster on event rate. In this model, the study was included as a random effect. Randomized controlled trials represented only a small portion of the total number of patients and follow-up time and so were described separately from cohort studies and excluded from the regression analysis.
For the CHA 2 DS 2 -VASc point score-stratified group of studies, we described study-specific stroke rates corresponding to CHA 2 DS 2 -VASc scores of 0, 1, or 2 points. We then categorized these rates as likely to confer low, indeterminate, or high expected net clinical benefit if included patients were treated with anticoagulants. An untreated stroke risk of <1% per year would confer low expected net clinical benefit, 1% to 2% per year would confer indeterminate net clinical benefit, and >2% per year would confer high net clinical benefit. We use the term "expected" in the decision analysis sense to indicate the predicted net balance of outcomes and their health impacts for average patients with AF in the given risk stratum. The stroke risk thresholds of 1% and 2% per year are based on a formal decision analysis that included estimated bleed risks, the health impact of stroke and bleed outcomes, and individuals' estimated life expectancies. 3 We report annualized stroke rates, which are accurate estimates of yearly stroke risks for the small rates, that are the focus of this article. 13 
RESULTS
Our initial literature search identified 3552 PubMed articles for screening. After a review of these entries' titles Prospective * * * * * * * *The Newcastle-Ottawa Scale assesses the quality of cohort study methodology across 3 categories and allows for scores of ≤4 stars for selection, 2 stars for comparability, and 3 stars for outcome, with more stars indicating higher quality.
†All studies within Japan-Shinken, Fushimi, and J-Rhythm (Pooled) analyses were assessed separately and had identical scores. and abstracts, 569 articles underwent full manuscript review. In order of decreasing exclusion priority, 103 manuscripts were excluded for not being a cohort study or randomized controlled trial (eg, a review article, research letter, or case-control study), 169 for not representing a general AF population, 47 for enrolling only anticoagulated patients, 162 for not having sufficient data to calculate a rate of ischemic stroke for the nonanticoagulated population, and 54 that were additional studies of a previously included cohort. This process left 34 studies, of which 17 were eligible for the overall stroke rate group only, 2 were eligible for the CHA 2 DS 2 -VASc score-stratified group only, and 15 were for inclusion in both groups (Figure 1 ). Figure 2 . Overall stroke rate in atrial fibrillation cohorts in order of descending stroke rate (events per 100 person-years) The study design and an assessment of study quality by the Newcastle-Ottawa Scale for each cohort included in overall stroke rate analysis is shown in Table 2. 6-8, Twenty-five cohorts were included in the overall stroke rate group, 10 of which were prospective and 15 of which used a retrospective design. The cohorts were of generally high quality, with only 2 studies receiving less than the highest possible score in each NewcastleOttawa Scale category.
The overall annualized stroke rates are displayed by study design and geographic region in Table 3 and in order of stroke rate in Figure 2 . [6] [7] [8] Of the 25 cohort studies, 7 were from North America, 8 from Europe, 8 from Asia, and 2 from the Middle East. The cohort studies represented 543 853 patients with AF not on OACs followed for 1 219 141 person-years. Cohorts ranged in size from 130 to 186 570 patients, and reported stroke rates ranged widely, from a low of 0.45% per year to a high of 9.28% per year. Seven randomized controlled trials represented only ≈ 1% of person-year follow-up and outcome events.
The Danish National Patient Registry, cited in both the AHA/ACC/HRS and ESC guidelines, had the second highest stroke rate and was significantly higher than all but 1 of the other cohorts (Table 3) . It is important to note that the Danish Diet, Cancer, and Health cohort had a stroke rate that was less than half the stroke rate reported from the Danish National Patient Registry. Similarly, the 186 570 patient analysis of the Taiwan National Health Insurance Research Database had a reported stroke rate more than twice that of the smaller 7920 patient random subset of that same database.
Cohort stroke rates were also significantly different across regions of origin, with the mean North American stroke rate being less than one-third that of the mean European rate (univariate P<0.0001) ( Table 3) . Stroke rates were also lower in cohorts with a prospective design as opposed to those using a retrospective design (1.22 vs 3.80, univariate P<0.0001).
Between-study variability in stroke rates was high, with a heterogeneity Q statistic of 5706.54 (P<0.0001) and an I 2 of 99.6%. In the mixed-effects model, where study was considered as a random effect, cohort region, prospective versus retrospective design, midpoint year of follow-up, and event cluster were not statistically significant (P=0.62, 0.11, 0.20, and 0.91, respectively).
The 17 cohorts reporting CHA 2 DS 2 -VASc scorestratified stroke rates are shown in Tables 4 and  5 . 6, 8, 14, 15, 17, 18, 20, 22, 25, 28, 30, 32, 34, 35, [44] [45] [46] As with the overall cohort stroke rates, wide variation was found in reported CHA 2 DS 2 -VASc point score stratum-specific rates, ranging manyfold for any given score. At a CHA 2 DS 2 -VASc score of 0, 13 of the 14 cohorts observed stroke rates of ˂1% per year, as did 13 of the 17 cohorts reporting rates at a CHA 2 DS 2 -VASc score of 1. At a CHA 2 DS 2 -VASc score of 1, only 3 of the 17 cohorts reported a stroke rate of ˃ 2% per year. At a CHA 2 DS 2 -VASc score of 2, 4 of 15 cohort studies reported stroke rates of ˂1% per year, 6 of 15 reported stroke rates between 1% and 2% per year, and only 5 of 15 reported stroke rates of ˃2% per year. It is notable that almost all North American cohorts reported stroke rates of ˂1% per year for patients with a CHA 2 DS 2 -VASc score of 0, 1, or 2.
DISCUSSION
The anticoagulation decision in patients with AF is logically based on the expected net clinical benefit of OACs, 47 The ESC and AHA/ACC/HRS guidelines base their anticoagulation recommendations on patients' risk of ischemic stroke tempered by a more informal assessment of bleed risk. 4, 5 Formal decision modeling indicates that the threshold of ischemic stroke risk for a favorable net clinical benefit from OACs is between 1% and 2% per year. 3 Guidelines suggest use of the CHA 2 DS 2 -VASc scoring system for determining the anticoagulation threshold, assuming that CHA 2 DS 2 -VASc scores correspond to fixed stroke rates. 4, 5 However, our study demonstrates wide variation in overall and point scorestratified stroke rates across AF cohorts both between and within geographic regions. Mixed effects regression analysis and an objective measure of study quality show that this between-study variation is not significantly accounted for by factors such as the Newcastle-Ottawa Scale score, calendar year, prospective versus retrospective cohort design, geographic region, or outcome event cluster. It is important to note that the AHA/ACC/ HRS and ESC guidelines do not highlight this variation in stroke rates but instead cite only stroke rates corresponding to CHA 2 DS 2 -VASc point scores, which support their recommended thresholds for anticoagulation. The ESC guidelines repeatedly cite the European cohort study with the highest reported stroke rates. 5, 6 The AHA/ACC/HRS guidelines support their thresholds for anticoagulation with a table of imputed, not observed, CHA 2 DS 2 -VASc point score-stratified stroke rates, acknowledging uncertainty in these rates only in the table footnote. 4 In fact, the rates listed in the AHA/ACC/HRS table are substantially higher than those from representative North American cohorts. Data from North American cohorts do not uniformly support the AHA/ACC/ HRS guideline's recommendation of anticoagulation for a CHA 2 DS 2 -VASc score of 2.
The reasons for the variation in stroke rates in different AF cohorts are unclear. These observations may reflect true differences in stroke rates across cohorts, but it is unlikely that true differences in stroke rates can explain wide differences in rates across cohorts with similar demographic features. For example, the Swedish Atrial Fibrillation Study reports stroke rates of 0.2% and 0.6% per year at CHA 2 DS 2 -VASc scores of 0 and 1, respectively, whereas the National Patient Registry from neighboring Denmark reports stroke rates 3 times higher at 0.78% and 2.01% per year at those same CHA 2 DS 2 -VASc point scores. 6, 22 Similarly, in 2011, Lin and colleague 14 used the Taiwanese National Health Insurance Database to report stroke rates of 0.35%, 0.5%, and 0.91% per year at CHA 2 DS 2 -VASc scores of 0, 1, and 2, respectively, whereas Chao and colleagues ,15 used a larger sampling from the same database in 2014 to report stroke rates of 1.15%, 2.11%, and 3.39% per year at those same respective scores, again over 3 times higher.
A more likely explanation is that differences in the methodology used when interrogating the underlying databases are responsible for much of the variation in reported stroke rates. This reasoning is supported by a repeat analysis of the Swedish Atrial Fibrillation Study data by Friberg et al 48 showing that by changing basic components of his methods-the length of the quarantine period (the period after AF diagnosis during which a thromboembolic outcome is not counted), whether the outcome was defined as ischemic stroke, thromboembolism excluding transient ischemic attacks, or ischemic stroke including transient ischemic attacks, and whether the outcome was a primary or secondary discharge diagnosis-they were able to produce overall annualized ischemic stroke rates ranging from 2.7% to 9.3% for the same AF cohort. Recent decades have witnesseda dramatic decrease in stroke rates. 49 However, we did not find a clear time trend, likely implying that the impact of varying methodologies may have obscured the effect of calendar year.
Although our literature search was extensive, we may have missed relevant cohorts. Such missed cohorts would not counter our primary observation of wide variation in observed stroke rates. Another potential limitation is that our study patients off anticoagulants may have taken antiplatelet agents, in particular aspirin. However, aspirin has only a weak stroke-preventive effect in AF. 50, 51 Last, we do not have enough data on each cohort's methodology to ensure consistency across the cohorts. For example, it is likely that the diagnosis of stroke risk factors (eg, hypertension) was not made consistently across studies. However, such methodological inconsistencies support our hypothesis that methodological differences across cohorts obscure the true ischemic stroke rates in these populations.
CONCLUSIONS
Significant and substantial variation occurred in reported stroke rates in different cohorts of patients with AF, even among cohorts from highly similar underlying populations. Our work makes clear that CHA 2 DS 2 -VASc point scores do not correspond to fixed absolute stroke rates, and this inconsistency between point scores and absolute stroke risk can substantially change the expected net clinical benefit of anticoagulation in any given patient with AF. These results call into question the generalizability of current leading guideline recommendations that CHA 2 DS 2 -VASc scores of 1 and 2 points should serve as the threshold for anticoagulant therapy use. Our findings highlight the need to standardize rigorous approaches to analyzing administrative and clinical databases. In the face of continued variation in point score-specific stroke rates, guideline recommendations should better reflect the uncertainty in defining the optimal threshold for use of anticoagulants for patients with AF.
